STK32C: A Potential Drug Target and Biomarker for Protein Kinase Inhibition

Target Name: STK32C

NCBI ID: G282974

STK32C

STK32C: A Potential Drug Target and Biomarker for Protein Kinase Inhibition

Structural and Functional Characterization of STK32C: A Potential Drug Target and Biomarker for Protein Kinase Inhibition

Introduction

Staurolactin kinase (STK) is a critical enzyme involved in cell signaling pathways, including G-protein-coupled receptor (GPCR) signaling, which plays a crucial role in cell survival, growth, and differentiation. STK has four isoforms, STK1, STK2, STK3, and STK4, which are expressed in different cell types and tissues. STK3, also known as STK-32C, is a 12kDa protein that is predominantly expressed in the brain and nervous system. It is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. As a result, STK3 has been considered as a potential drug target for the treatment of neurodegenerative diseases.

In this article, we will focus on the structural and functional characterization of STK32C, including its potential as a drug target and biomarker. We will discuss the structure of STK32C, its unique features, and its involvement in different signaling pathways. We will also provide insights into the potential clinical applications of STK32C as a drug target and biomarker.

Structure and Mechanism of STK32C

STK32C is a 12kDa protein that consists of 354 amino acid residues. It has a unique open-loop structure, which is typical of protein kinases. The protein has a N-terminal domain that contains a nucleotide-binding oligomerization domain (NBO), which is responsible for nucleotide binding. The NBO is composed of a nucleotide-binding oligomerization loop (NBO loop) and a nucleotide-binding oligomerization loop (NBO-loop-like) region. The NBO loop is the site of the protein's catalytic activity, where STK32C interacts with nucleotides to regulate protein activity.

The STK32C protein also has a C-terminal domain that contains a catalytic active site, which is responsible for protein-protein interactions and catalytic activity. The catalytic active site is composed of a unique Rossmann-fold (RF) and a hydrogen bonding network, which are unique features of protein kinases. The RF is a specific binding site for small molecules, such as inhibitors, which can inhibit the protein's catalytic activity. The hydrogen bonding network is a network of hydrogen bonds that are formed between the protein's amino acids, which is unique for protein kinases.

Function of STK32C

STK32C is involved in various cellular processes, including cell adhesion, migration, and survival. It plays a crucial role in the regulation of cell-cell adhesion by activating the integrin protein alpha-2 (伪2) on the cell surface. This process is essential for the maintenance of tissue architecture and the development of tissues.

STK32C is also involved in the regulation of cell migration. It plays a role in the regulation of the progress(P) and the reversed (R) forms of the microtubule, which are responsible for cell transport. The P form of the microtubule is involved in the regulation of cell growth, while the R form is involved in the regulation of cell survival.

In addition to its role in cell adhesion and migration, STK32C is also involved in the regulation of cell survival. It has been shown to play a role in the regulation of apoptosis, which is a natural form of cell death. regulate the expression of genes involved in cell apoptosis, including Bcl-2. This suggests that STK32C may be a potential drug target for the treatment of neurodegenerative diseases.

Potential Clinical Applications of STK32C

The potential clinical applications of STK32C as a drug target are vast. As discussed above, STK32C has been shown to play a role in the regulation of

Protein Name: Serine/threonine Kinase 32C

The "STK32C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STK32C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets